Limited Prognostic Value of Changes in Antineutrophil Cytoplasmic Antibody Titers in Patients with Wegener’s Granulomatosis

  • Gail S. Kerr
  • Thomas A. Fleisher
  • Claire W. Hallahan
  • Randi Y. Leavitt
  • Anthony S. Fauci
  • Gary S. Hoffman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 336)

Abstract

One hundred and six patients with Wegener’s granulomatosis (WG) were studied for the presence of antineutrophil cytoplasmic antibodies (ANCA). In 53 patients serial ANCA determinations were obtained. C-ANCA positivity was a sensitive (88%) marker of active WG. However, changes in serial titers were temporally concordant with a change in disease status in only 55% of patients. Furthermore, a rise in c-ANCA titer preceded clinical exacerbation of disease in only 24% of patients who had been in remission or had low grade, smoldering disease. A rise in c-ANCA titer alone should not be considered a priori evidence of impending relapse, and does not justify modification of immunosuppressive therapy.

Keywords

Toxicity Tuberculosis Sedimentation Methotrexate Glucocorticoid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohen Tervaert, J.W.C., Huitema, M.G., Hene, R.J., Sluiter, W.J., 1990, Prevention of relapses in Wegener’s granulomatosis by treatment based on anti-neutrophil cytoplasmic antibody titer, Lancet 336: 709–711.CrossRefGoogle Scholar
  2. Cohen Tervaert, J.W., Fokko, J., van der Woude, M.D., Fauci, A.S., Ambrus, J.L., Velosa, J., Keane, W.F., Meijer, S., van der Jiessen, M., Hauw, The, T., van der Hem, G.K., Kallenberg, C.G.M., 1989, Association between active Wegener’s granulomatosis and anticytoplasmic antibodies, Arch Intern Med. 149: 2461–2465.Google Scholar
  3. Fauci, A.S., Haynes, B.F., Katz, P., Wolff, S.M., 1983, Wegener’s granulomatosis: prospective clinical and therapeutic experience in 85 patients, Ann Intern Med 98: 76–85.PubMedCrossRefGoogle Scholar
  4. Hoffman, G.S., Kerr, G.S., Leavitt, R.Y., Hallahan, C.W., Lebovics, R.S., Travis, W.D., Rottem, M., Fauci, A.S., 1992, Wegener’s granulomatosis: an analysis of 158 patients, Ann Intern Med. 116: 488–498.PubMedCrossRefGoogle Scholar
  5. Specks, U., Wheatley, C.L., McDonald, T.J., Rohrbach, M.S., DeRemee, R.A., 1989, Anticytoplasmic autoantibodies in the diagnosis and followup of Wegener’s granulomatosis, Mayo Clin Proc. 64: 28–36.PubMedCrossRefGoogle Scholar
  6. van der Woude, F.J., Rasmussen, N., Lobatto, S., Wiik, A., Permin, H., van Es, L.A., van der Giessen, M., van der Hem, G.K., The, T.H., 1985, Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis, Lancet 1: 425–429.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Gail S. Kerr
    • 1
  • Thomas A. Fleisher
    • 2
  • Claire W. Hallahan
    • 1
  • Randi Y. Leavitt
    • 1
  • Anthony S. Fauci
    • 1
  • Gary S. Hoffman
    • 1
  1. 1.Laboratory of ImmunoregulationNational Institute of Allergy and Infectious DiseasesBethesdaUSA
  2. 2.Clinical PathologyClinical Center National Institutes of HealthBethesdaUSA

Personalised recommendations